Madecassoside

Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB^[5][6], exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity^[10]. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases. In Vitro:Madecassosid (30, 100 μmol/L, 12 h) increases cell viability of oxidative injuried human umbilical vein endothelial cells (HUVECs)^[5].
Madecassosid (10-100 μmol/L, 12 h) inhibits phosphorylation of p38 MAPK and activaty of Caspase-3, and therefore exhibits an antiapoptotic activity^[5].
Madecassosid (10-100 μg/L) exhibits anxioxidative activity against melanocyte dendtrites retraction, maintaining mitochondrial membrane potential and Ca²⁺ homeostasis^{[7]< /sup>.
Madecassosid (30 μM) improves Insulin secretion by increasing expressions of p-IRS1, Akt and p-Akt under glucotoxic conditions[8].
Madecassosid (10 μM, 24 h) prevents inflammation and autophagy of neuronal cells induced by Aβ_25–35 through the class III PI3K/Beclin-1/Bcl-2 pathway[9].
In Vivo:Madecassosid (6, 12, 24 mg/kg, i.v.) resolves neurological deficit and ameliorates neuronal apoptosis after focal cerebral ischemia reperfusion[6].
Madecassosid (6, 12, 24 mg/kg, i.v) inhibits activity of NF-kB and so prevents the brain injury[6].
Madecassosid (120 mg/kg, i.g.) reduces LPS-induced neurotoxicity and enhances heme oxygenase proteins via upregulation of Nrf2 in LPS-stimulated neurotoxicity[10].
Madecassosid (10-40 mg/kg,p.o.) ameliorates oxidative damage and imflammation after bleomycin (BLM) instillation, inhibits TGF-β1 overexpression and collagen synthesis, improves collagen degradation[11].}